Skip navigation

Current DateTime: 06:51:17 14 Nov 2009
LinksList Documentid: 24355697
New drug can help smokers quit, review finds
By: Reuters | 24 Jan 2007 | 11:33 AM ET
Text Size
Prescription-only pill beats placebo in helping people kick the habit

NEW YORK - Smokers who use the prescription-only anti-smoking agent varenicline triple their likelihood of successfully kicking the habit, compared with trying to quit without medication, a new review concludes.

Pfizer’s varenicline was approved in 2006 by the Food & Drug Administration under the trade name Chantix and by European regulators under the trade name Champix.

The drug partially stimulates nicotine receptors in the brain, which helps reduce nicotine withdrawal symptoms. It also partially blocks nicotine from attaching to these receptors, making smoking less satisfying and so curbing a person’s desire to smoke.

Dr. Kate Cahill, from Oxford University, U.K. and colleagues analyzed data from six Pfizer-sponsored studies that compared the effects of varenicline with placebo. Three of these also included a comparison with bupropion, an antidepressant that is also used for smoking cessation. The six trials included 4,924 smokers, 2,451 of whom used varenicline.

The results are reported in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research.

In the pooled analysis, Cahill and her colleagues found that people who took a varenicline pill twice daily increased their odds of being continuously cigarette-free at one year approximately three-fold compared with people assigned a placebo. Success rates were also 1.6-times greater with varenicline than bupropion.

The jury remains out on the value of varenicline in helping ex-smokers from taking up smoking again.

The main side effect of varenicline is mild to moderate nausea, which subsides with time, the researchers say.

“Additional and independent randomized trials of varenicline are needed to confirm the early findings from industry trials,” Cahill’s team concludes. “There is also a need for direct comparisons with nicotine replacement therapy; and for further trials with bupropion, to establish the relative efficacy of the treatments.”

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:02:14 14 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:14 14 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:02:14 14 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:14 14 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters